Efficacy Measures: PFS, ORR, OS, & Subset Analyses

Efficacy Measures: PFS, ORR, OS, & Subset Analyses
THE AXIS TRIAL: A PHASE 3 TRIAL IN 2nd-LINE mRCC
A phase 3, multicenter, open-label, head-to-head trial vs sorafenib (N=723)
References
  1. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
  2. Data on file. Pfizer Inc, New York, NY.
  3. Motzer RJ, Escudier B, Tomczak P. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552-562.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer V.2.2019. ©National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed September 27, 2018. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.